Ketamine is Leading the Psychedelic Revolution: Here’s How to Invest
July 19th, 2021
App, Exclusive, Psychedelics, Top Story
The FDA approval of Johnson & Johnson’s Spravato®—an esketamine nasal spray for treatment-resistant depression—marked the start of the psychedelic revolution. While ketamine was well-known as an anesthetic and party drug, the regulatory approval opened the door to treating the leading cause of disability worldwide—depression.
Ketamine alleviates the symptoms of depression in a matter of hours, compared to weeks for antidepressants. Rather than affecting monoamine neurotransmitters like antidepressants (e.g., serotonin or dopamine), it acts on glutamate, the most common chemical messenger in the brain, which plays an important role in the synaptic changes that underlie memory.
Let’s look at ketamine’s growing role as a treatment for mental health conditions and how to invest in the drug that’s leading the psychedelics revolution.
Ketamine Clinics on the Rise
Most physicians use intravenous ketamine in the ER or OR setting as an anesthetic, but there’s a growing demand for outpatient ketamine infusions for mood and pain disorders. Ketamine Startup reckons that there are more than 200 outpatient ketamine clinics in the United States and these figures continue to rise as consumer awareness grows.
Health insurance has been a key barrier. Until recently, insurance companies have refused to cover ketamine infusions due to the lack of clinical research. Since the approval of Spravato in 2019, these companies have become more and more willing to cover part of insurance claims for generic ketamine infusions targeting chronic pain and mental health.
The body of research supporting ketamine also continues to grow. In mid-2020, the FDA expanded Spravato’s approvals to include patients having suicidal thoughts or those that have recently attempted to take their own lives. Researchers found that more than 40% of suicidal patients that received four weeks of treatment had greatly reduced depressive symptoms.
The combination of rising consumer awareness, growing evidence of efficacy, and health insurance coverage paints a very bullish picture for the future of ketamine clinics and treatments. Given the high level of efficacy reported in clinical research, these treatment centers could provide frontline support for mental health disorders.
Investing in Ketamine’s Growth
Investors have many options to invest in ketamine’s growth potential. For example, many companies are developing FDA-approved ketamine therapies targeting a wide range of mental health conditions. Other companies are building a nationwide footprint of ketamine clinics that could eventually expand to include other psychedelic therapies, like psilocybin.
Ehave Inc.’s (OTC Pink: EHVVF) KetaDASH aims to become the glue connecting patients with ketamine clinics and therapies. Through its web and mobile app, patients can easily create a profile, check the availability of medical professionals, and schedule appointments. Patients and medical professionals can also use the platform to manage therapies over time.
KetaDASH’s easy-to-use dashboard. Source: KetaDASH
In addition to KetaDASH, the company partnered with Brain Scientific to leverage data and artificial intelligence to correlate biomarkers for the identification of chronic pain, depression, general anxiety, ADHD, schizophrenia, and other mental health conditions. The company aims to correlate ketamine treatment and patient improvements.
Click here to receive an investor presentation and corporate updates
All these efforts also tie into its overarching goal of aggregating health data and analyzing it with machine learning algorithms to diagnose mental health disorders to evaluate treatment options. The company recently announced a partnership with Health Wizz and BurstIQ to enhance privacy and streamline the collection and organization of medical records.
Ketamine is the first psychedelic therapy to go mainstream following the FDA approval of Spravato® for treatment-resistant depression and suicidal ideations. Investors can participate in ketamine’s upside potential in a variety of ways, but eHave Inc. (OTC Pink: EHVVF) is taking one of the most innovative approaches through its KetaDASH and wider data-driven strategy.
For more information, visit the company’s website or download their investor presentation.
Click here to receive an investor presentation and corporate updates
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.